Switzerland
· Delayed Price · Currency is CHF Kuros Biosciences AG Company Description
Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally.
It operates through two segments, Medical Devices and Legacy Portfolio. The company offers MagnetOs Granules, an original advanced bone graft based on the submicron needle-shaped NeedleGrip surface technology; MagnetOs Putty, a mold uses to fill bony voids for intervertebral disc space or posterolateral spine; and Attrax, a biphasic calcium phosphate bone grafts that mimic the porous and trabecular structure of cancellous bone, as well as checkmate licensing.
The company was incorporated in 2016 and is headquartered in Schlieren, Switzerland.
| Country | Switzerland |
| Founded | 2016 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 122 |
| CEO | Christopher Fair |
Contact Details
Address: Wagistrasse 25 Schlieren, 8952 Switzerland | |
| Phone | 41 44 733 4747 |
| Website | kurosbio.com |
Stock Details
| Ticker Symbol | KURN |
| Exchange | SIX Swiss Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CHF |
| ISIN Number | CH0325814116 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Christopher T. Fair B.B.A. | Chief Executive Officer and Director |
| Daniel Geiger | Chief Financial Officer |
| Sjoerd Musters | Chief Operating Officer and GM of BV |
| Dr. Joost D. de Bruijn B.Sc. Ph.D., Ph.D. | President of Innovation and Strategy and Executive Director |
| G. Joseph Ross | Senior Vice President of Marketing and Business Development |
| Nikki Coleman | Vice President of Global Human Resources |
| Dr. Philippe Saudan Ph.D. | Chief Development Officer |
| John Griffin | Chief Commercial Officer |
| Dr. Katherine Sage D.O., FAAOS, M.S. | Senior Vice President of Medical and Clinical Affairs |
| Dr. Virginia Jamieson | Consultant |